← Back to patent-cliff list
CAS 1213234-53-7
(2R,3R,4S,5R,6R)-6-((pivaloyloxy)methyl)tetrahydro-2H-pyran-2,3,4,5-tetrayl tetrakis(2,2-dimethylpropanoate)
Codes: DAPA-014, CANA-017
Application context (from source-drug indications)
Type 2 diabetesDapagliflozin Propanediol/Metformin HydrochlorideEnd-stage renal diseaseCanagliflozin/Metformin HydrochlorideCardiac and vascular disordersCanagliflozin/Metformin HydrochlorideAbdominal aortic aneurysmCanagliflozin/Metformin HydrochlorideType 2 diabetesCanagliflozin/Metformin HydrochlorideChronic renal impairmentDapagliflozin Propanediol MonohydrateHeart failureDapagliflozin Propanediol MonohydrateKidney diseaseDapagliflozin Propanediol MonohydrateType 1 diabetesDapagliflozin Propanediol MonohydrateType 2 diabetesDapagliflozin Propanediol MonohydratePolycystic ovary syndromeDapagliflozin Propanediol MonohydrateType 2 diabetesCanagliflozin HemihydrateDiabetic nephropathyCanagliflozin HemihydrateCoronary artery lesionCanagliflozin HemihydrateDiabetesCanagliflozin HemihydrateHeart failureCanagliflozin HemihydrateEnd-stage renal diseaseCanagliflozin Hemihydrate
Source drugs (routes using this intermediate)
| Drug | Tier | Expiry |
|---|---|---|
| Dapagliflozin Propanediol/Metformin Hydrochloride | Tier A — Act now | 2030 |
| Canagliflozin/Metformin Hydrochloride | Tier B — Position early | 2029 |
| Dapagliflozin Propanediol Monohydrate | Tier B — Position early | - |
| Canagliflozin Hemihydrate | Tier C — Watch / trade | - |
Position in synthesis routes (up/downstream chain)
Ordered by route registration; left → right is the synthesis direction. The highlighted node is the current CAS; others link to their own profiles.
(5-bromo-2-chlorophenyl)(4-ethoxyphenyl)methanone→(2S,3R,4S,5S,6R)-6-(hydroxymethyl)tetrahydro-2H-pyran-2,3,4,5-tetraol→pivaloyl chloride→(2R,3R,4S,5R,6R)-6-((pivaloyloxy)methyl)tetrahydro-2H-pyran-2,3,4,5-tetrayl tetrakis(2,2-dimethylpropanoate)→(2R,3R,4S,5R,6R)-2-bromo-6-((pivaloyloxy)methyl)tetrahydro-2H-pyran-3,4,5-triyl tris(2,2-dimethylpropanoate)→(2S,3S,4R,5R,6R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-((pivaloyloxy)methyl)tetrahydro-2H-pyran-3,4,5-triyl tris(2,2-dimethylpropanoate)
2-(4-fluorophenyl)-5-(5-iodo-2-methylbenzyl)thiophene→(2S,3R,4S,5S,6R)-6-(hydroxymethyl)tetrahydro-2H-pyran-2,3,4,5-tetraol→(2R,3R,4S,5R,6R)-6-((pivaloyloxy)methyl)tetrahydro-2H-pyran-2,3,4,5-tetrayl tetrakis(2,2-dimethylpropanoate)→(2R,3R,4S,5R,6R)-2-bromo-6-((pivaloyloxy)methyl)tetrahydro-2H-pyran-3,4,5-triyl tris(2,2-dimethylpropanoate)→(2S,3S,4R,5R,6R)-2-(3-((5-(4-fluorophenyl)thiophen-2-yl)methyl)-4-methylphenyl)-6-((pivaloyloxy)methyl)tetrahydro-2H-pyran-3,4,5-triyl tris(2,2-dimethylpropanoate)
(5-bromo-2-chlorophenyl)(4-ethoxyphenyl)methanone→(2S,3R,4S,5S,6R)-6-(hydroxymethyl)tetrahydro-2H-pyran-2,3,4,5-tetraol→pivaloyl chloride→(2R,3R,4S,5R,6R)-6-((pivaloyloxy)methyl)tetrahydro-2H-pyran-2,3,4,5-tetrayl tetrakis(2,2-dimethylpropanoate)→(2R,3R,4S,5R,6R)-2-bromo-6-((pivaloyloxy)methyl)tetrahydro-2H-pyran-3,4,5-triyl tris(2,2-dimethylpropanoate)→(2S,3S,4R,5R,6R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-((pivaloyloxy)methyl)tetrahydro-2H-pyran-3,4,5-triyl tris(2,2-dimethylpropanoate)
2-(4-fluorophenyl)-5-(5-iodo-2-methylbenzyl)thiophene→(2S,3R,4S,5S,6R)-6-(hydroxymethyl)tetrahydro-2H-pyran-2,3,4,5-tetraol→(2R,3R,4S,5R,6R)-6-((pivaloyloxy)methyl)tetrahydro-2H-pyran-2,3,4,5-tetrayl tetrakis(2,2-dimethylpropanoate)→(2R,3R,4S,5R,6R)-2-bromo-6-((pivaloyloxy)methyl)tetrahydro-2H-pyran-3,4,5-triyl tris(2,2-dimethylpropanoate)→(2S,3S,4R,5R,6R)-2-(3-((5-(4-fluorophenyl)thiophen-2-yl)methyl)-4-methylphenyl)-6-((pivaloyloxy)methyl)tetrahydro-2H-pyran-3,4,5-triyl tris(2,2-dimethylpropanoate)
Intermediates available on this site
No listed intermediates for this target yet — send an RFQ directly and it will enter our matching pool.
This is a CAS-level registry record: registrations across routes are merged. Supplier offers and buyer demands will be matched on this CAS as the primary key.